BDX · Becton Dickinson & Co
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Feb 10, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Feb 10, 2026.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow non-GAAP | $1.7B | the first nine months of fiscal year 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDX
this stock
Becton Dickinson & Co
|
$51.81B | — | +8.2% | — | 3.4% |
|
ISRG
Intuitive Surgical Inc
|
$131.36B | -35.2% | +20.5% | 42.7 | 2.0% |
|
MDLN
Medline Inc.
|
$46.36B | -17.5% | +11.5% | — | 2.8% |
|
ALC
Alcon Inc
|
$35.13B | -8.3% | +10.5% | — | 2.5% |
|
RMD
Resmed Inc
|
$34.00B | -2.1% | +13.4% | 22.6 | 8.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Feb 10, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDX | +0.3% | +13.7% | +12.6% | +13.6% | — |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -0.8% | +9.7% | -2.1% | +10.4% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.